Don't show this message again

Meet Us at American Association for the Study of Liver Diseases (AASLD) 2024 The Liver Meeting

Meet Us at the 62nd Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2024

Meet Us at American Association for the Study of Liver Diseases (AASLD) 2024 The Liver Meeting.

Glucagon engagement is essential for the direct anti-inflammation and anti-fibrosis effect of efocipegtrutide in TAA-induced mouse model of liver injury and fibrosis

Poster Number: 1084

Session: Poster Session I, Nov 15 2024 at 1:00 PM ~ 2:00 PM (GMT-7)

Presenter: Yohan Kim
/ Hanmi Pharmaceutical
yohan.kim@hanmi.co.kr

Meet Us at the 62nd Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2024.

Safety and efficacy of efpegerglucagon in patients with congenital hyperinsulinism: interim results from a phase 2 study

Poster Number: P1-309

Session: P1 printed Poster, Nov 16 at 10:00 AM ~ 6:00 PM GMT, Exhibition Hall

Presenter: Antonia Dastamani /
Great Ormond Street Hospital, UK
Antonia.Dastamani@gosh.nhs.uk

Hanmi's New Story

Soaring Towards a
Shared Future,
Unveiling
a New Chapter of Hanmi

Innovation

Korea's leading R&D-centric healthcare company.
We create never-before-seen innovation through bold challenges.

Respect, Trust, Integrity

We lead the global healthcare industry
through Respect, Trust, and Integrity.

The Hanmi Way

No path started as a path.
We seek a better future for humanity on it.

Latest News

Hanmi Pharmaceutical and Beijing Hanmi Progress Clinical Trials of Co-developed BH3120 as a Next-Generation Cancer Immunotherapy

2024.11.25

Hanmi Unveils its Next-Generation ‘MAT2A Inhibitor’ Targeting Metabolic Vulnerabilities of Cancer Cells

2024.10.29

Researchers from Hanmi R&D Center present groundbreaking findings at the EORTC-NCI-AACR 2024

Hanmi Pharmaceutical Partners with Tabuk Pharmaceuticals through an Exclusive License and Supply Agreement for Innovative Value-Added Medicines in the MENA Region

2024.10.10

Ju Hyun Lim, Vice Chairman of Hanmi and Ismail Shehada, CEO of Tabuk Pharmaceuticals are taking a commemorative photo af

Focus on Making
Innovative Medicines

Hanmi Pharmaceutical is leading innovation in the
pharmaceutical industry with a sustainable R&D
infrastructure covering various therapeutic areas.

Obesity/Metabolism

Developing best-in-class drugs for obesity,
non-alcoholic steatohepatitis,
and more with multiple mechanisms of action

CDMO

Bio

We have global competitiveness in the manufacturing and developing of biopharmaceuticals such as recombinant proteins based on microbial culture and biochemical reaction processes.

Fine Chemical

Based on our diverse API experience, Hanmi Fine Chemical is focusing on challenging CDMO businesses such as complicated peptides, PEG, and NTP.

Chemical

The cutting-edge ICT-based Paltan Smart Plant, with an annual production capacity of over 6 billion tablets, supplies the world with high-quality synthetic medicines optimized to global standards.

ESG Report

Hanmi ESG is Everyday-life Innovation

Your dream is our future.
Hanmi awaits you.

Join Us

Meet Us at American Association for the Study of Liver Diseases (AASLD) 2024 The Liver Meeting.

Meet Us at the 62nd Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2024.